FDA Clears SkinStylus for Periorbital Wrinkles; Accepts Biofrontera sNDA for sBCC; Belite Bio Completes Tinlarebant NDA

The U.S. Food and Drug Administration has cleared the SkinStylus SteriLock MicroSystem for the improvement of periorbital wrinkles in adults aged 22 years and older across all Fitzpatrick skin types, while also accepting for review Biofrontera's supplemental New Drug Application seeking to expand Ameluz photodynamic therapy to superficial basal cell carcinoma. Separately, Belite Bio has completed its rolling submission of a New Drug Application for tinlarebant, an investigational oral therapy for Stargardt disease.

SkinHealth Systems (NASDAQ: SKIN), the company behind the Hydrafacial brand, announced that the FDA cleared the SkinStylus microneedling device for periorbital wrinkle improvement. SkinStylus is now the only microneedling device with FDA-cleared indications for facial acne scars, periorbital wrinkles, and abdominal hypertrophic scars. The U.S. microneedling market is estimated at $330 million in 2025, with consumer spend growing 33% year-over-year. One in five Hydrafacial consumers also received microneedling in the prior year, and 90% of Hydrafacial consumers report interest in combined Hydrafacial–microneedling treatments. Following the news, SKIN shares gained 36.95%, adding approximately $36 million to the company's valuation.

Biofrontera announced that the FDA has accepted for review its sNDA seeking to expand the indication of aminolevulinic acid hydrochloride topical gel (Ameluz), used in combination with the RhodoLED red-light lamp series, to include treatment of superficial basal cell carcinoma (sBCC). The FDA reported no filing deficiencies and assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 28, 2026. Basal cell carcinoma is the most common malignancy in the United States, with approximately 3.6 million cases diagnosed annually, and estimates indicate that 10% to 25% of these cases represent the superficial subtype. Ameluz is currently approved in the U.S. for the treatment of actinic keratosis. The therapy combines a topical photosensitizing agent with red light exposure to generate reactive oxygen species that selectively destroy targeted cells.

Belite Bio has completed the rolling submission of its NDA to the FDA for tinlarebant, an investigational once-daily oral tablet for the treatment of Stargardt disease type 1 (STGD1). The submission follows less than three months after the company initiated the rolling process. Tinlarebant has received both Fast Track and Breakthrough Therapy designations for its STGD1 indication, and its NDA package was submitted under Breakthrough Therapy designation. Phase 3 data from the global DRAGON trial is at the center of the submission. The completed application will undergo a 60-day review period, and a PDUFA target action date will be assigned only if the FDA accepts the submission. Based on tinlarebant's designations, its priority review eligibility means the review period may be six months instead of the standard ten months. The oral therapy has the potential to become the first FDA-approved treatment for Stargardt disease.